Hydralazine injection warnings: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Hydralazine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIU..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==WARNINGS== | |||
In a few patients, hydralazine may produce a clinical picture simulating [[systemic lupus erythematosus]] including [[glomerulonephritis]]. In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see [[Hydralazine injection precautions|PRECAUTIONS, Laboratory Tests]]).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c3797028-c625-4f70-ae69-8a5f6f23f1b8 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 06:12, 11 March 2014
| Hydralazine |
|---|
| HYDRALAZINE tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| HYDRALAZINE injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Hydralazine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
WARNINGS
In a few patients, hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests).[1]
References
- ↑ "HYDRALAZINE HYDROCHLORIDE INJECTION [FRESENIUS KABI USA, LLC]". Retrieved 10 March 2014.